EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY

Stefan Schreiber  ¹     Nicholas Powell  ²     Florian Rieder  ³     Anita Afzali  ⁴     Yi Luo  ⁵     Mark T. Osterman  ⁵     Chun Wu  ⁵     Lisu Wang  ⁵     Courtney Radosti  ⁵     Aditya Patel  ^5    
1 University Hospital Schleswig-Holstein, Kiel, Germany
² Imperial College London, London, United Kingdom
³ Digestive Diseases and Surgery Institute Cleveland Clinic, Cleveland, United States
⁴ The Ohio State University Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology, and Nutrition, Columbus, United States
⁵ Bristol Myers Squibb, Princeton, United States

Topic
IBD, Nurses, Primary Care

Session
Clinical trials in ulcerative colitis II

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)